BMS-684

• Description :

  BMS-684 is a selective DGKα inhibitor with an IC50 of 15 nM. BMS-684 inhibits DGKα kinase activity with >100-fold selectivity over the related DGK type I family members DGKβ and DGKγ. BMS-684 does not inhibit any of the other seven DGK isozymes[1].

• CAS Number :

  [313552-29-3]

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  DGK

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bms-684.html

• Purity :

  99.76

• Solubility :

  DMSO : 14.29 mg/mL (ultrasonic; warming)

• Smiles :

  CN(C1=CC=CC=C1C(N2CCN(C(C3=CC=CC=C3)C4=CC=CC=C4)CC2)=C5[N+]([O-])=O)C5=O

• Molecular Formula :

  C27H26N4O3

• Molecular Weight :

  454.52

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Michael Wichroski, et al. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity. Sci Transl Med. 2023 Oct 25;15 (719) :eadh1892.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported